Is ALT a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Differentiated GLP-1/glucagon profile, with product revenue at None (clinical-stage). The bear case rests on altimmune is a single-asset, clinical-stage company with no approved products and no revenue, so a failed or disappointing Phase 3 readout could sharply reduce the stock, and the Phase 3 MASH data are not due until 2029, leaving years of funding needs before that answer arrives. Analysts covering it are spread from $11.00 to $28.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Altimmune is a single-asset, clinical-stage company with no approved products and no revenue, so a failed or disappointing Phase 3 readout could sharply reduce the stock, and the Phase 3 MASH data are not due until 2029, leaving years of funding needs before that answer arrives. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $11.00, +400.0% from the $2.20 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Differentiated GLP-1/glucagon profile. Pemvidutide is designed to deliver meaningful weight loss while preserving lean muscle mass, a profile management argues could differentiate it from pure GLP-1 agonists. The most optimistic analyst target on ALT is $28.00, +1172.7% from the $2.20 price. That figure is only reachable if this thesis works close to its best case.

Altimmune is a single-asset, clinical-stage company with no approved products and no revenue, so a failed or disappointing Phase 3 readout could sharply reduce the stock, and the Phase 3 MASH data are not due until 2029, leaving years of funding needs before that answer arrives. It competes in obesity against Novo Nordisk and Eli Lilly, which have vastly greater scale, marketing, and pipelines. Even positive trials carry regulatory and commercialization risk, and the company will likely need additional capital over a multi-year development path, which can dilute existing shareholders; the April 2026 offering already did so. The share price has fallen to its 52-week low even as the trials advanced, which shows how little near-term support clinical milestones have given the stock. The most pessimistic published target is $11.00, +400.0% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Altimmune is a clinical-stage biopharmaceutical company focused on metabolic and liver disease.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Differentiated GLP-1/glucagon profile) stalling in the reported numbers rather than in the narrative, the risk above (altimmune is a single-asset, clinical-stage company with no approved products and no revenue, so a failed or disappointing Phase 3 readout could sharply reduce the stock, and the Phase 3 MASH data are not due until 2029, leaving years of funding needs before that answer arrives) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

It depends on your risk tolerance. Bulls cite positive Phase 2b MASH data, a positive Phase 2 alcohol use disorder trial, Breakthrough and Fast Track designations, and a cash position larger than the market cap. Bears note it is a single-asset, pre-revenue biotech whose Phase 3 MASH data are not due until 2029 and that it faces giant competitors. ALT suits investors who accept high volatility and possible total loss, not conservative buyers. This is not investment advice, and Walnut is not an investment adviser.

Altimmune is a clinical-stage biopharmaceutical company developing pemvidutide, a GLP-1/glucagon dual agonist, for obesity and MASH (metabolic dysfunction-associated steatohepatitis, a serious fatty-liver disease). It has no approved products and is focused on advancing pemvidutide through clinical trials toward potential regulatory approval.

Pemvidutide is Altimmune's lead drug candidate, a once-weekly injectable that activates both the GLP-1 and glucagon receptors. It is designed to produce weight loss while preserving lean muscle mass and improving liver health, and is being studied in both obesity and MASH, where it reported positive Phase 2b results.